Dr. Patrick E. Sewell
Patrick E. Sewell, M.D., is CEO, Founder and Chief Scientist at Triple Helix Science and an Interventional Oncologist at Regenerative Methods Corporation in Los Cabos, Mexico. He has spent more than three decades in interventional radiology, and since 1999 has worked to establish interventional oncology as a discipline of its own, performing several of the first image-guided tumor ablation procedures ever attempted in humans.
Patrick founded Triple Helix Science in January 2024 and leads it as its chief scientist. The company develops IP-protected therapeutics across gene therapy, regenerative medicine, stem cell science, and longevity science, with programs spanning oncology, neurodegeneration, metabolic health, fertility, muscle biology, and healthy aging. It works closely with 199 Biotechnologies, the London partial-reprogramming and gene therapy company, on moving those therapies toward human application and wider access.
His 2026 publication record concentrates on the biology of aging and on the practical problem of getting therapeutic cargo where it needs to go. Read The guardian paradox: DNA damage response overactivation as an integrative driver of aging — a tumor suppressor–negative regulator framework in Aging, Clinical rationale for thymic restoration in adult immunosenescence in Immunity & Ageing, Grip strength as a systems biomarker of aging: neuromuscular junction constraints and biomarker decoupling in gene therapy in Frontiers in Aging, and Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access in Frontiers in Drug Delivery.
Alongside that work he has run his own practice, Regenerative Methods, as President and Owner since September 2017, combining gene therapy, stem cell therapy, regenerative tissue grafting, and minimally invasive image-guided surgery across Central America and Europe. His interventional oncology practice continues in parallel.
Read Intradural Extramedullary Spinal Cord Malignancy Treated With Percutaneous Image-Guided Cryoablation, a 2025 Cureus case report in which cryoablation cleared a recurrent spinal malignancy that surgery, chemotherapy, and embolization immunotherapy had all failed to control.
Between March 2024 and March 2025, Patrick served as Chief of Clinical and Research Gene Therapy at 199 Biotechnologies in London, directing the conception, design, and international clinical trials of new gene therapies with a focus on oncology and longevity.
From July 2024 to May 2025, he was Cofounder and Chief Scientist at Triplhelix, where he led development of gene and cell therapies for antiaging, cancer, and heritable genetic disease, oversaw gene therapy manufacturing, and ran physician education programs. Between May 2017 and May 2024, he worked as a gene therapy specialist at GenequestX.
Earlier, as Director of Clinical Affairs, he led the dual gene therapy dementia study reported by BioViva in 2021, in which five patients with mild to moderate dementia received intranasal hTERT and Klotho gene transfer. All five showed sustained improvement on the Folstein examination against an expected decline of roughly three points per year, with telomere lengthening and no reported complications.
He is a coinventor, with our Elizabeth Parrish and our Jason R. Williams, on US patent 12564646, Treatment of age-related cognitive decline using genetically modified viral vectors, granted to BioViva USA in March 2026. He practiced as an Interventional Oncologist at the Williams Cancer Institute in Cabo San Lucas between September 2022 and July 2023, and ran an image-guided cancer therapy practice in Mexico City from April 2015 to October 2022.
Patrick was Assistant Professor of Radiology and Surgery at the University of Mississippi Medical Center from July 1996 to June 2005, where he also served as Chief of the Division of Interventional Oncology. In 1999, he performed the world's first radiofrequency ablation of a lung tumor there, a procedure the Mississippi Legislature formally commended in 2000. He developed the first MRI-guided cryoablation performed in the United States in 1998, and in March 2000 carried out the world's first interventional-MRI cryosurgery of a uterine fibroid.
Between 1999 and 2008, he consulted for Boston Scientific and Galil Medical, designing their interventional oncology radiofrequency probe line, writing the clinical treatment algorithms for lung, kidney, uterine, and bone ablation, and codesigning the argon-based percutaneous MRI cryoablation system. He founded the medical imaging company Sapheneia, which he owned from 2005 to 2014, and which commercialized radiation-reduction and image-enhancement technology across several continents, and was President and Owner of Delta Radiology between 2009 and 2014.
He earned his M.D. from the Louisiana State University School of Medicine in Shreveport, now LSU Health Shreveport, in 1991, completing an internal medicine year and a diagnostic radiology residency there through 1996. He then took two postdoctoral fellowships at the University of Mississippi Medical Center, the first in neuro, body, and vascular interventional radiology from 1996 to 1997 and the second in cross-sectional imaging from 1997 to 1998. He earned a Bachelor of Applied Science in Biology and Physics from Centenary College of Louisiana in 1986.
Patrick served on the faculty of the Age Management Medicine Group CME conference in Florida in 2020, and he lectures internationally on ablation technique and gene therapy. Listen to Patrick Sewell MD: Gene Therapy for Alzheimer's and Longevity on Health Longevity Secrets. Watch A New Era Against Cancer, Dementia, and Aging With Genes, his conversation with Dr. Esra Çavuşoğlu on the Ayık Kafa podcast.
He is based in San José del Cabo, Baja California Sur, Mexico, and practices across several continents.
Visit his LinkedIn profile and ResearchGate profile. Follow him on Facebook and X.